Results 101 to 110 of about 57,515 (223)
Limited Prognostic Value of c-erbB-2 Compared to uPA and PAI-1 in Primary Breast Carcinoma
The International Journal of Biological Markers, 2003 In a retrospective study of 488 women with primary breast cancer, after a median follow-up of 10 years, we sought interactions between disease-free survival (DFS) and overall survival (OS) and tumor antigen levels of two components of the plasminogen ...
C. Bouchet +4 more
doaj +1 more source
Molecular Oncology, Volume 20, Issue 11, Page 2741-2763, November 2026.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Ovarian Carcinoma: Signal Pathways and Clinical Studies
MedComm, Volume 7, Issue 11, November 2026.This review synthesizes current knowledge on the pathophysiological mechanisms driven by the Notch, HER2, DNA damage repair (DDR), PI3K/AKT/mTOR, and angiogenesis (VEGF) pathways in ovarian cancer. A key focus is placed on summarizing subsequent targeted therapeutic strategies, detailing the landscape of associated clinical trials and their ...
Yanru Long +3 more
wiley +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
British Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
ErbB receptor signaling directly controls oligodendrocyte progenitor cell transformation and spontaneous remyelination after spinal cord injury [PDF]
, 2019 We recently discovered a novel role for neuregulin-1 (Nrg1) signaling in mediating spontaneous regenerative processes and functional repair after spinal cord injury (SCI).
Galino, Jorge +14 more
core +2 more sources
Scientific Reports, 2017 Current pathophysiological models of schizophrenia focus on neurodevelopmental and immunological mechanisms. We investigated a molecular pathway traditionally linked to the neurodevelopmental hypothesis (neuregulin 1 - ErbB), and pathogen-associated ...
Szabolcs Kéri +2 more
doaj +1 more source
New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer
Cancer Science, Volume 117, Issue 11, Page 2901-2909, November 2026.Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi +2 more
wiley +1 more source
, 2007 The ErbB family of receptor tyrosine kinases regulates cell growth, differentiation, and tumorigenesis. This dissertation contains two independent studies of ErbB-1 and ErbB-4.
Thiel, Kristina Wyatt
core
Structure-function analysis of nucleolin and ErbB receptors interactions.
PLoS ONE, 2009 BackgroundThe ErbB receptor tyrosine kinases and nucleolin are major contributors to malignant transformation. Recently we have found that cell-surface ErbB receptors interact with nucleolin via their cytoplasmic tail.
Keren Farin +3 more
doaj +1 more source
iScienceSummary: ERBB receptor tyrosine kinases are involved in development and diseases like cancer, cardiovascular, neurodevelopmental, and mental disorders.
Lukša Popović +10 more
doaj +1 more source